Skip to main content
. 2022 Jan 29;17:25. doi: 10.1186/s13023-022-02178-z

Table 1.

Distribution of respondents (n = 181) by patient advocacy groups

Patient group N (%)
National Mucopolysaccharidosis Society (USA) 100 (55.2%)
United Kingdom Mucopolysaccharidosis Society 36 (19.9%)
Duke Pompe Clinical and Research Group (USA) 24 (13.3%)
International Gaucher Alliance 12 (6.6%)
Instituto Vidas Raras (Brazil) 9 (5%)